Metformin and prostate cancer mortality: a meta-analysis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Purpose Observational studies report conflicting results on the association between metformin exposure and prostate cancer outcomes. This meta-analysis summarizes studies reporting overall survival, prostate cancer-specific mortality, and biochemical recurrence. Methods PubMed and Embase were systematically reviewed to identify studies investigating the association between metformin use and clinical endpoints among men with prostate cancer while taking confounding by diabetes diagnosis into account. Pooled risk estimates (hazard ratios, HRs) and 95 % confidence intervals (CIs) were calculated using random-effects models. Sensitivity analyses for quality components and factors for heterogeneity were conducted. Results Of 549 articles identified, nine retrospective cohort studies representing 9,186 patients were included. There was significant heterogeneity between studies, and studies differed in quality. Metformin use was associated with improved overall survival in studies with clear risk window definition (HR 0.88, 95 % CI 0.86-0.90, p Conclusions This meta-analysis suggests a benefit of metformin in men with diabetes and prostate cancer. However, further carefully designed studies are needed to confirm findings and to assess potential generalization to non-diabetic, non-white, and less aggressively treated men with prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“hyperinsulinemia and hyperglycemia may promote a microenvironment amenable to cancer cell proliferation with activation of mitogenic signaling.1778”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1778]
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
IntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetes Care · doi:10.2337/dc06-9912 · Cited by 1,203
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 531
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Dotan, Z. A., Bianco, F. J., Lilja, H., & Scardino, P. T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0756 · Cited by 529
A meta-analysis of diabetes mellitus and the risk of prostate cancer
Kasper, J. S., & Giovannucci, E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0410 · Cited by 491
Self-citationShapiro, S. (1997) · PubMed · Cited by 299
Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes
Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G., Austin, P. C., & Fleshner, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7043 · Cited by 271
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 270
Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up
Popiolek, M., Rider, J. R., Andrén, O., Andersson, S.-O., Holmberg, L., Adami, H.-O., & Johansson, J.-E. (2013) · European Urology · doi:10.1016/j.eururo.2012.10.002 · Cited by 226
Self-citationXu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
Spratt, D. E., Zhang, C., Zumsteg, Z. S., Pei, X., Zhang, Z., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.12.004 · Cited by 180
Metabolic alterations and targeted therapies in prostate cancer
Flavin, R., Zadra, G., & Loda, M. (2011) · The Journal of Pathology · doi:10.1002/path.2809 · Cited by 178
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 161
Rothermundt, C. A., Hayoz, S., Templeton, A. J., Winterhalder, R., Strebel, R. T., Bärtschi, D., Pollak, M., Lui, L., Endt, K., Schiess, R., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.12.057 · Cited by 130
Association Between Metformin Use and Risk of Prostate Cancer and Its Grade
Margel, D., Urbach, D. R., Lipscombe, L. L., Bell, C. M., Kulkarni, G. S., Austin, P. C., & Fleshner, N. E. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt170 · Cited by 96
Clinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin
Patel, T., Hruby, G. W., Badani, K. K., Abate-Shen, C. T., & McKiernan, J. M. (2010) · Urology · doi:10.1016/j.urology.2010.03.059 · Cited by 90
Pretreatment Predictors of Time to Cancer Specific Death After Prostate Specific Antigen Failure
D'Amico, A. V., Cote, K., Loffredo, M. J., Renshaw, A. A., & Chen, M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000049200.30192.d1 · Cited by 80
Yu, H., Yin, L., Jiang, X., Sun, X., Wu, J., Tian, H., Gao, X., & He, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116327 · Cited by 77
A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer
Joshua, A. M., Zannella, V. E., Downes, M. R., Bowes, B., Hersey, K. M., Koritzinsky, M., Schwab, M. G., Hofmann, U., Evans, A., van der Kwast, T., et al. (2014) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.20 · Cited by 77
Type 2 diabetes and the risk of mortality among patients with prostate cancer
Bensimon, L., Yin, H., Suissa, S., Pollak, M., & Azoulay, L. (2014) · Cancer Causes & Control · doi:10.1007/s10552-013-0334-6 · Cited by 71
Raval, A. D., Thakker, D., Vyas, A., Salkini, M., Madhavan, S. S., & Sambamoorthi, U. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2014.52 · Cited by 67
Attner, B., Landin‐Olsson, M., Lithman, T., Noreen, D., & Olsson, H. L. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-9946-5 · Cited by 63
Effect of metformin on prostate cancer outcomes after radical prostatectomy
Kaushik, D., Karnes, R. J., Eisenberg, M. S., Rangel, L. J., Carlson, R. E., & Bergstralh, E. J. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.05.005 · Cited by 58
Allott, E. H., Abern, M. R., Gerber, L., Keto, C. J., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., Cooperberg, M. R., Moorman, P. G., et al. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.48 · Cited by 58
Häggström, C., Stocks, T., Nagel, G., Manjer, J., Bjørge, T., Hallmans, G., Engeland, A., Ulmer, H., Lindkvist, B., Selmer, R. M., et al. (2014) · Epidemiology · doi:10.1097/ede.0000000000000174 · Cited by 48
The Use of Metformin in Patients with Prostate Cancer and the Risk of Death
Bensimon, L., Yin, H., Suissa, S., Pollak, M., & Azoulay, L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0056 · Cited by 46
Patorno, E., Garry, E. M., Patrick, A. R., Schneeweiß, S., Gillet, V. G., Zorina, O., Bartels, D. B., & Seeger, J. D. (2015) · Drug Safety · doi:10.1007/s40264-015-0280-1 · Cited by 31
Lee, H., Kuk, H., Byun, S., Lee, S. E., & Hong, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124761 · Cited by 26
The Time Is Ripe for a Randomized Trial of Metformin in Clinically Localized Prostate Cancer
Penney, K. L., & Stampfer, M. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7715 · Cited by 18
Spratt, D. E., Zhang, Z., & Zeléfsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.04.015 · Cited by 4
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
“Five meta-analyses have examined the effect of metformin on OS [22, 23, 25–27], two of which also investigated prostate CSS [25, 26].”
BackgroundRepurposing metformin for the prevention of cancer and cancer recurrence
Heckman-Stoddard, B. M., DeCensi, A., Sahasrabuddhe, V. V., & Ford, L. G. (2017) · Diabetologia · doi:10.1007/s00125-017-4372-6 · Cited by 297
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
Sharma, P., & Kumar, S. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0398-0 · Cited by 108
Metadata
- Authors
- Stopsack, K. H., Ziehr, D. R., Rider, J. R., & Giovannucci, E. L.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Stopsack, Konrad H.
- Venue
- Cancer Causes & Control
- Published
- 2015-11-04
- Volume
- 27
- Issue
- 1
- Pages
- 105-113
- ISSN
- 0957-5243 (ISSN-L)
- 1573-7225
- OpenAlex
- W1896360033
- Cited by
- 72
- References
- 43
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 14 · 2016: 14
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Causes & Control (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- metformin, prostate cancer, prostate cancer mortality, overall survival, biochemical recurrence, diabetes mellitus, immortal time bias, drug repurposing
- MeSH terms
- Diabetes Mellitus, Humans, Male, Metformin, Prostatic Neoplasms, Retrospective Studies, Risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.